Work

REMEDi4ALL - Standard Operating Procedure - Two drug combination test: detection of synergetic anti-proliferative effect in cancer cell lines

Year: 2025

Type: article

Abstract: This SOP describes the application of the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) for detection of the synergetic anti-proliferative effect in pancreatic cancer cell lines based on small molecule treatment. It describes the procedure of compound- and cell-preparation to detect and analyse the anti-proliferative synergetic effect of compounds. IMPORTANT: for each new cell line and each new tested compound pair the cell number/well and the specific CC50s of tested compounds should be evaluated before the application of this SOP. See also Standard Operating Procedure SOP-R4A-1.1 “Drugs combination screening”

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.17293604

Author: Kuzikov, Maria

Institution: Fraunhofer Institute for Translational Medicine and Pharmacology

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: European Commission